bioRxiv ScienceSearch

Biology subjects

Qiao, S.

Publications and source records attributed to Qiao, S..

2 recordsLinked to original sources

Enhancement of Macrophage Function by the Antimicrobial Peptide Sublancin Protects Mice from Methicillin-Resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) is the major pathogen responsible for community and hospital bacterial infections. Sublancin, a glocosylated antimicrobial peptide isolated from Bacillus subtilis 168, possesses anti-bacterial infective effects. In this study, we investigated the role and anti-infection mechanism of sublancin in a mouse model of MRSA-induced sublethal infection. Sublancin could modulate innate immunity by inducing the production of IL-1{beta}, IL-6, TNF- and nitric oxide, enhancing phagocytosis and MRSA-killing activity in both RAW264.7 cells and peritoneal macrophages. The enhanced macrophage function by the peptide in vitro correlated with stronger protective activity in vivo in the MRSA-invasive sublethal infection model. Macrophages activation by sublancin was found to be mediated through the TLR4 and the NF-{kappa}B and MAPK signaling pathways. Moreover, oral administration of sublancin increased the frequencies of CD4+ and CD8+ T cells in mesenteric lymph nodes. The protective activity of sublancin was associated with in vivo augmenting phagocytotic activity of peritoneal macrophages and partly improving T cell-mediated immunity. Macrophages thus represent a potentially pivotal and novel target for future development of innate defense regulator therapeutics againt S. aureus infection.

immunology

Association of Arg389Gly β1-adrenergic receptor polymorphism with effective dose of β blocker in congestive heart failure among Chinese Han population

BackgroundTo investigate the relationship between {beta}1-adrenergic receptor (ADRB1) gene polymorphisms and the response to medication in patients with congestive heart failure (CHF).\n\nMethods and ResultsTwo hundred and sixty patients with CHF were enrolled. Ser49Gly and Arg389Gly polymorphisms were identified. During one-year follow-up, differences of echocardiographic parameters and major adverse cardiac events (MACE) were analyzed. For Ser49Gly polymorphisms, there were no differences between AA genotype and AG/GG genotype of baseline clinical features and echocardiographic parameters as well as one-year incidence of MACE. For Arg389Gly polymorphisms, there were no significant differences in baseline clinical characteristics, LVDd and LVEF among the three genotypes. However, the increase amplitude of LVEF after one year among patients carrying GG genotype was significantly higher than those carrying CC genotype (11.7% vs 1.3%, P<0.05). The incidence of MACE among different genotypes of CC, CG and GG were 22.2%, 10.0% and 8.3%,with statistical difference (P=0.021).\n\nConclusionsThe study suggested there was no relationship between Ser49Gly polymorphisms of the ADRB1 gene and the therapeutic effect and prognosis in CHF patients under the same dosage of drugs. However, the improvement of cardiac function and prognosis in patients carrying the Gly389 allele were significantly better than those of Arg389Arg homozygous.

genetics